Glycyrrhizin reduced BA accumulation and partly ameliorated NASH not by directly enhancing FXR, but by restoring inflammation impaired FXR signaling, which in turn upregulated SHP and suppressed CYP7A1 (Yan et al., 2018a). This evidence concerns the gene NR0B2 and metabolic dysfunction-associated steatohepatitis.